2025-12-03 - Analysis Report
Here's a breakdown of the provided information and a comprehensive analysis:

**1. Return Rate Comparison:**

*   **TEM (Tempus AI Inc.) Cumulative Return:** 34.23%
*   **S&P 500 (VOO) Cumulative Return:** 29.59%
*   **Divergence:** Current: 9.8, Relative Divergence: 43.8
*   **Company Overview:** Tempus AI Inc. is a company focused on applying artificial intelligence in healthcare, particularly in oncology, to personalize treatment.

**Analysis:**

*   TEM has outperformed the S&P 500 (VOO) in cumulative return by 4.64% (34.23%-29.59%).
*   The divergence of 9.8 places it in the middle of its historical divergence range.
*   The relative divergence of 43.8 suggests that while outperforming the S&P 500, TEM's performance relative to its own historical volatility is near the average.

**Alpha, Beta Analysis:**

|            | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2023-2025  | 34.0%  | 76.7%  | 6.0%   | 0.3  | 13.4   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** A 34.0% CAGR is a strong growth rate.
*   **MDD (Maximum Drawdown):** A 76.7% MDD is substantial, indicating high volatility and potential for significant losses from peak to trough.
*   **Alpha:** An alpha of 6.0% suggests TEM has outperformed its benchmark index after accounting for risk.
*   **Beta:** A beta of 0.3 indicates that TEM is significantly less volatile than the market (S&P 500).
*   **Cap(B):** The 13.4B market capitalization classifies it as a Large-Cap.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 75.2
*   **Last Market Close:** Price: 75.185, Previous Close: 74.07, Change: 1.51
*   **5-day SMA:** 76.648
*   **20-day SMA:** 73.4559
*   **60-day SMA:** 82.9285

**Analysis:**

*   The stock price is currently above its 20-day SMA but below its 5-day and 60-day SMAs.
*   The 5-day SMA above the current price suggests a short-term downward trend.
*   The 20-day SMA below the current price suggests a medium-term upward trend.
*   The 60-day SMA significantly above the current price suggests a longer-term downward trend.

**3. Indicators & Signals:**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI:** 56.21 (Neutral, neither overbought nor oversold)
*   **PPO:** 1.62 (Positive, indicating upward momentum)
*   **Hybrid Signal:** Buy 100% of cash (14 shares - Very Safe) Monthly invest 5.0% of total investment ($1,000.00)
*   **Recent (20 days) relative divergence change:** -2.9 (Short-term decline)
*   **Expected Return (%):** NaN

**Analysis:**

*   The MRI suggests a highly recommended investment.
*   The RSI indicates neutral momentum.
*   The positive PPO suggests upward momentum but is not particularly strong.
*   The hybrid signal recommends buying and continuing to invest.
*   The negative change in relative divergence suggests a recent short-term underperformance compared to the S&P 500.
*   The "Expected Return" being NaN means there is no reliable estimation on potential return.
*   The recent price change of 1.51 is above the average.

**4. Recent News & Significant Events:**

*   **Positive Sentiment:** Several articles highlight positive aspects: "Earnings Surge and New Lymphoma Research Partnership," "Great Buying Opportunity," and analysts' opinions.
*   **Analyst Interest:**  Reports mention Level Four Advisory Services LLC's stock position and discussions on FDA clearance.
*   **Volatility Concerns:** Articles address "Earnings Volatility" and suggest monitoring MACD trends.

**Analysis:**

*   News is mixed, with positive coverage surrounding earnings, research partnerships, and analyst recommendations, but also focuses on volatility and the need to monitor trends.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (~2.14)
*   **Target Price:** Average: 91.42, High: 105.00, Low: 80.00

**Analysis:**

*   Analyst consensus is generally positive.
*   The average target price of $91.42 suggests a potential upside from the current price.

**5. Comprehensive Analysis:**

Tempus AI (TEM) has outperformed the S&P 500 in the period examined, although its own historical volatility is near average. The company exhibits strong growth potential (34.0% CAGR), but also high risk (76.7% MDD). The Market Risk Indicator recommends TEM as a highly investable.

Recent news is mixed, with positive reports on earnings and partnerships countered by concerns about volatility. Analyst opinions are generally positive, with a buy consensus and a target price indicating upside.

**Overall, TEM appears to be a potentially high-growth but also high-risk investment. The positive analyst sentiment and recent positive news are encouraging, but investors should be aware of the potential for significant price fluctuations. It is recommended to perform a more detailed analysis of the company's fundamentals, competitive landscape, and risk factors before making any investment decisions.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.